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impairment in aged rats via microglial activation
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Abstract
Background: Neuroinflammation is considered a risk factor for impairments in neuronal function and cognition that
arise with trauma, infection, and/or disease. IL-17A has been determined to be involved in neurodegenerative diseases
such as multiple sclerosis. Recently, IL-17A has been shown to be upregulated in lipopolysaccharide(LPS)-induced
systemic inflammation. This study aims to explore the role of IL-17A in LPS-induced neuroinflammation and cognitive
impairment.
Methods: Male Sprague–Dawley (SD) rats were injected intraperitoneally with LPS (500 μg/kg), and IL-17A expression in
serum and in the hippocampus was examined 6, 12, 24, and 48 h later. Then, we investigated whether IL-17A-neutralizing
antibodies (IL-17A Abs, 1 mg/kg) prevented neuroinflammation and memory dysfunction in aged rats that received LPS
(500 μg/kg) injection. In addition, the effect of IL-17A on microglial activation in vitro was determined using ELISA and
immunofluorescence.
Results: LPS injection increased the expression of IL-17A in serum and in the hippocampus. IL-17A Abs improved
LPS-induced memory impairment. In addition, IL-17A Abs prevented the LPS-induced expression of TNF-α, IL-6
and inflammatory proteins, and of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) as well as
the activation of microglia in the brain. IL-17A Abs also inhibited the expression of amyloid precursor protein
(APP) and BACE1 and increased the expression of the synaptic marker PSD95 in the aged rats treated with LPS. In
an in vitro study, we found that recombinant IL-17A could simulate microglial activation and increase production
of pro-inflammatory cytokines.
Conclusion: Taken together, our results suggest that IL-17A was involved in LPS-induced neuroinflammation and
cognitive impairment in aged rats via microglial activation. Anti-IL-17A may represent a new therapeutic strategy
for the treatment of endotoxemia-induced neuroinflammation and cognitive dysfunction.
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Introduction
Neuroinflammation plays a key role in neurodegenera-
tive diseases such as Alzheimer’s disease and multiple
sclerosis (MS) and in memory impairment [1–3]. The
elderly are vulnerable to the adverse effects of injec-
tions on cognitive function, and the aging process
itself is associated with enhanced neuroinflammatory
processes involving polarized microglial responses and
the production of pro-inflammatory cytokines, with a
bias towards M1 and away from M2 activation states [4, 5].
LPS, an endotoxin isolated from bacteria, stimulates
pro-inflammatory cascades by acting through plasma
membrane proteins, such as toll-like receptor 4 (TLR4),
causing pro-inflammatory cytokines to be produced. Sys-
temic injection of LPS induces neuroinflammation and
amyloidogenesis in the hippocampus [6]. LPS-induced
neuroinflammation in animal models has also been dem-
onstrated to cause memory impairment [7].
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Microglia, the resident immune cells in the brain,
execute principal inflammatory feedback in various
neurodegenerative conditions of the brain. It has been
reported that microglia likely play an important role in
either the development of protective immune responses or
in the progression of damaging inflammation during central
nervous system (CNS) disease states [8]. However, uncon-
trolled activation of microglia leads to the excessive release
of various cytokines, such as tumor necrosis factor-alpha
(TNF-α), prostaglandin E2 (PGE2), interleukin-6 (IL-6),
nitric oxide (NO), and reactive oxygen species (ROS), which
have been implicated in various neurodegenerative diseases.
Thus, inhibition of the exaggerated inflammatory response
by activated microglial cells helps to attenuate the severity
of neurodegenerative diseases [9, 10].
IL-17A is the main member of the IL-17 family of
cytokines, which includes five other members, desig-
nated IL-17A-F, and is secreted by a subset of T (Th17)
cells. Although IL-17A alone is a weak inducer of target
genes, it has been shown to synergize with IL-1β, IL-22,
IFN-γ, TNF-α, and other cytokines in vivo [11]. Notably,
IL-17A is strongly involved in mediating pro-inflammatory
responses via the induction of many other cytokines,
including IL-6, TGF-β, and TNF-α as well as the induction
of chemokines, including IL-8 and monocyte chemotactic
protein-1 (MCP-1), in many cell types [12]. IL-17A plays an
important role in the active states of autoimmune diseases
such as MS, during which patients’ clinical symptoms are
exacerbated [13]. Recently, IL-17A has been shown to be
upregulated in lipopolysaccharide (LPS)-induced systemic
inflammation. The present study aims to explore the role of




Dulbecco’s modified Eagle’s medium (DMEM), 0.25 %
Trypsin-EDTA solution, fetal calf serum (FCS), peni-
cillin/streptomycin, and poly-D-lysine were purchased
from Gibco–BRL (Grand Island, NY, USA). LPS (Coli
0111:B4) was purchased from Sigma–Aldrich (St. Louis,
MO, USA). RIPA buffer and the BCA kit were purchased
from Beyotime (Shanghai, China). Rat recombinant IL-
17A protein, fluoroshield mounting medium with 4,6-dia-
midino-2-phenylindole (DAPI), and mouse anti-OX42
monoclonal antibody were purchased from Abcam (Hong
Kong, China). The rat IL-17A ELISA kit was obtained from
Biolegend (San Diego, CA, USA, Cat. no. 437907). Rat IL-
6 ELISA kit (R600B) and TNF-α ELISA kit (RTA00)
were obtained from R&D Systems, Inc. (Minneapolis,
MN, USA). Rabbit anti-Iba1 and anti-PSD95 polyclonal
antibodies were purchased from Abcam (Hongkong,
China). Rabbit monoclonal antibodies against BACE1,
iNOS, COX-2, GAPDH (14C10), and rabbit polyclonal
anti-APP antibody and anti-rabbit secondary antibody
were all purchased from Cell Signaling (Boston, MA,
USA). A FITC-conjugated goat anti-rabbit IgG antibody
was purchased from Santa Cruz (Santa Cruz Biotechnology,
USA).
Animals
Male SD rats aged 18 months were purchased from Jinling
Hospital of Nanjing University and used in this study (n =
70). All rats were housed in groups of five per cage during
the experimental period, with water and food available ad
libitum. Ambient temperature of the housing and testing
rooms was 22 ± 1 °C. Rats were housed under a 12-h
light–dark cycle. The study was approved by the Nanjing
Medical University Animal Care and Use Committee, and
the experiments were performed according to the Guide
for the Care and Use of Laboratory Animals of the National
Institutes of Health of the United States.
Drug administration
LPS
To induce a systemic inflammatory reaction for the
experimental procedures, LPS from Escherichia coli (Sigma
Chemical, St Louis, MO, USA; 0111:B4) was diluted in sa-
line and injected intraperitoneally (IP) at a dose of 500 μg/
kg. This dose was used for the induction of moderate
inflammation [14]. Additionally, it has been reported that
this dose is within the range that does not affect motor
activity [15]. Control rats were IP injected with saline only.
IL-17A antibodies
A mouse anti-rat IL-17A antibody (Sangon Biotech Co.,
Ltd., China; 1 mg/kg) was diluted in saline, which were
specific to IL-17 (Additional file 1: Figure S1), and adminis-
tered intracerebroventricularly (ICV). A total volume of
3 μl (200 μg/μl) was injected before LPS administration.
Thirty minutes before LPS/saline administration, rats were
anesthetized with isoflurane (1 %), mounted in a stereotaxic
frame, and kept at 37 °C using a heating pad. A burrhole
was made to inject into the lateral ventricle at the following
coordinates (relative to Bregma): 1.5 mm to the right and
0.8 mm posterior. A 33-gauge needle connected to a 10-μl
syringe was then lowered 3.7 mm, and either IL-17A Abs
or saline (3 μl) was injected at a rate of 1 μl/min. The nee-
dle was then left in place for 2 min before being removed
to suture the skin. The rats were then placed on a heating
pad to recover. Once the rats had regained normal mobility,
they were returned to their home cage with unlimited
access to food and water and checked regularly for 12 h to
ensure there were no adverse effects from surgery.
Design and treatment groups
First, 30 rats were randomly divided into five groups (n = 6)
as follows: (1) saline (2.5 ml/kg) control group; (2) LPS-
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treated groups: rats were IP injected with LPS, respectively
for 6, 12, 24, and 48 h. Then, 40 rats were randomly divided
into four groups (n = 10). Two groups were challenged
with an acute dose of LPS (n = 20; IP administration)
while two groups received saline (n = 20; IP administra-
tion). Of the LPS groups, one group received IL-17A Abs
via ICV administration (n = 10; anti-IL-17A + LPS group)
and a control group received saline also via ICV adminis-
tration (n = 10; LPS group). Similarly with the saline-
treated rats, one group received IL-17A Abs through
ICV injection (n = 10; anti-IL-17A group) while the
other group received saline also through an ICV injec-
tion (n = 10; control group). The study design is briefly
illustrated in Fig. 1.
Cell cultures
Primary rat microglial cells were prepared as previously
described, with minor modifications [16]. Briefly, whole
brains were isolated from SD rats at postnatal day 1–2.
The meninges and blood vessels were removed completely
in cold D-Hank’s buffered saline. Next, the brains were
minced with sterile scissors and digested with 0.25 %
Trypsin-EDTA solution for 10 min at 37 °C. Trypsiniza-
tion was stopped by adding an equal volume of culture
medium, which was high-glucose DMEM containing 10 %
FBS and penicillin (100 U/ml)/streptomycin (100 μg/ml).
The dissociated cells were passed through a 100-μm-pore
mesh, pelleted at 1500 rpm for 5 min, and resuspended in
culture medium. The cells were seeded on poly-D-lysine-
precoated cell culture flasks and cultured at 37 °C in a
humidified atmosphere of 5 % CO2/95 % air. After seed-
ing, the medium was replaced every 3–4 days. After the
glial cells formed a confluent monolayer (10–14 days), the
microglial cells were separated from the astrocytes by
shaking for 5 h at 150 rpm. The microglial cells were
seeded into 6-well culture plates at a density of 105 cells/
cm2. After 24 h of culture, the cells were starved overnight
and then subjected to treatments. The purity of the micro-
glia was confirmed to be >98 % using immunofluores-
cence staining for OX-42 (CD11b) and was calculated as
follows: number of OX-42 positive cells/number of DAPI
positive cells.
Behavioral analysis
Trace fear conditioning (TFC)
TFC was used to assess hippocampal-dependent mem-
ory in rodents as previously described [17, 18]. Rats
were trained to associate an environment (context) with a
conditional stimulus (tone) and an unconditional stimulus
(foot shock). The training paradigm was performed as pre-
viously described [18]: tone duration, 20 s; level, 80 dB;
shock duration, 2 s; and intensity, 0.8 mA. The IP LPS
injection was performed 30 min after the fear conditioning
paradigm, and IL-17A Abs were given immediately after
the fear conditioning paradigm. During training, an initial
exploratory phase (100 s) was followed by two trials sepa-
rated by a 100-s intertrial interval. Trials consisted of a 20-s
auditory cue (80 dB, 5 kHz, conditional stimulus), followed
by a 2-s foot shock (0.8 mA, unconditional stimulus). Rats
anticipate the shock by “freezing,” which is defined as the
absence of all movement expect for respiration; this defen-
sive posture reflects learned fear. When placed in the same
context on a subsequent occasion, the learned fear is
recalled and the amount of learning and recall is measured
by the amount of freezing. Contextual memory of the
learned fear was assessed 1 day after the LPS injection by
returning the rat to the same chamber in which it was
trained, in the absence of the tone and shock. Freezing
behavior was automatically scored for 300 s by video track-
ing software (Xeye Fcs, Beijing MacroAmbition S&T De-
velopment Co., Ltd., Beijing, China).
Y maze
The Y maze consisted of three arms (regions I–III, 30-
cm l × 5-cm w × 20-cm h), with the arms at a 120° angle
from each other [19]. Each arm had a lamp at the distal
end. A safe region was associated with the illumination,
whereas the other regions featured electrical foot stimu-
lation (40 ± 5 V). Each rat was first placed at the end of
one arm (starting area chosen randomly) and allowed to
move freely in the maze during a 3-min session without
any stimulation to adapt to the environment. The test
was then started, and the illuminated arm (safe region)
served as the new starting area. Furthermore, we changed
the orientation of the safe and stimulation regions using a
randomization method. The test was considered to be suc-
cessful (learned) if the rat reached the safe region within
10 s. After each foot stimulation, we waited for the rat to
reach the illuminated arm (the new starting area) before
the next stimulation. If nine responses were correct in 10
Fig. 1 Study design. a The hippocampus and serum were
collected at 6, 12, 24, and 48 h after LPS injection. b Rats were
injected with LPS within 30 min after TFC training, and the IL-17A
Abs were administrated immediately after TFC training. The
hippocampus and serum were collected 24 h after LPS injection.
Behavioral tests were also performed at this time point
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consecutive foot stimulations (9/10 standard), the mice
were defined as having reached the learning criterion. The
total number of stimulations to reach the criterion during
training was recorded as the learning ability. All rats
reached the learning criterion in the present study.
Immunohistochemistry
The cerebral tissues were harvested, fixed with 4 % para-
formaldehyde, and then immersed in 15 % sucrose at 4 °C
for 24 h followed by 30 % sucrose for 48 h. Sections (10-
μm-thick) were prepared. We blocked endogenous perox-
idase activity with 3 % H2O2 in PBS solution for 10 min.
Sections were then incubated with the Iba1 polyclonal
antibody (1:200) at 4 °C overnight and then incubated
with secondary antibody for 2 h. Microglial cells were
visualized by adding DAB to the sections. Activated micro-
glia were identified as Iba1-positive cells. For quantification
[20, 21], the studied tissue sections were selected with a
150-μm interval according to anatomical landmarks corre-
sponding to Bregma from Bregma −2.8 to −3.8 mm of the
rat brain (Paxinos and Watson, 1996). For each animal, 15
photographs from the CA1 area of three hippocampus
sections and 15 photographs from the CA3 area of three
hippocampus sections were captured using Leika 2500
(Leica Microsystems, Wetzlar, Germany) at 200× magnifi-
cation. The number of Iba1-positive cells per photograph
(0.74-mm2 frame) was obtained by using NIH ImageJ soft-
ware (Bethesda, MD, USA), averaged and converted to
cells/mm2. Iba1-positive cell counting was performed in a
blinded fashion by an experimenter that was unaware of
the sample identity.
ELISA
The levels of TNF-α and IL-6 in serum, brain tissue ex-
tracts, and culture medium were measured with ELISA kits
from R&D Systems (Minneapolis, MN, USA). The levels of
IL-17A in serum and brain tissue extracts were measured
with an ELISA kit from Biolegend (San Diego, CA, USA).
Western blotting
Hippocampi were homogenized in RIPA buffer. The
homogenates were centrifuged for 15 min at 12,000 g
at 4 °C. The quantity of protein in each supernatant was
determined using a BCA protein assay kit. Proteins (60 μg)
were denatured with sodium dodecyl sulfate (SDS) sample
buffer and separated using 10 % SDS-polyacrylamide gel
electrophoresis (PAGE). The proteins were transferred to a
polyvinylidene fluoride (PVDF) microporous membrane
(Millipore, Bedford, MA, USA), which was then blocked
with 5 % skim milk for 1 h at room temperature. The
membrane was incubated with primary antibody overnight
at 4 °C. The following primary antibodies were used: rabbit
polyclonal anti-APP, -iNOS, -COX-2, and -BACE1 and
mouse monoclonal anti-GAPDH (1:1000). After adding
the anti-rabbit or anti-mouse secondary antibody
(1:1000) for 1 h, the protein bands on the membranes
were detected with ECL kits (Thermo Fisher Scientific,
Rockford, IL, USA). The relative density of the protein
bands was scanned by densitometry using Image Lab
software (Bio-Rad, Richmond, CA, USA) and quantified
by NIH ImageJ software (Bethesda, MD, USA).
Immunofluorescence
To determine microglial activation, cells were fixed with
4 % paraformaldehyde for 30 min; non-specific binding was
blocked by incubating cells in a 5 % BSA and 0.1 % Triton
X-100 solution for 1 h at room temperature. The microglial
cells were incubated with rabbit anti-Iba1 polyclonal anti-
body (1:500) in the blocking solution overnight at 4 °C.
After three washes with PBS, the microglial cells were
incubated with the corresponding FITC-conjugated goat
anti-rabbit IgG (1:200) for 2 h at room temperature and
the nuclei were stained with DAPI. Fluorescence images
were acquired using a Leica TCS SP2 (Leica Microsystems,
Buffalo Grove, IL, USA) laser scanning spectral confocal
microscope. Quantification was made using the associated
Leica LCS software by placing a rectangular region of inter-
est (ROI) across the full image and within the ROI, for
every image, mean fluorescence intensity (MFI) was mea-
sured and the values were plotted.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
5 software (version 5.01, GraphPad Software, San Diego,
CA, USA). The results are expressed as the mean ± s.e.m.
Data were analyzed with one-way ANOVA followed by
Newman-Keuls post hoc test wherever appropriate. A P <
0.05 was considered to be a statistical significance.
Results
Increases of IL-17A expression induced by LPS
To examine whether IL-17A is involved in LPS-induced
neuroinflammation, we studied IL-17A protein expression
levels in the serum and in the hippocampus within 48 h
after LPS injection. The ELISA data showed that levels of
IL-17A in serum and in the hippocampus were signifi-
cantly higher in the rats challenged by LPS (Fig. 2a, b).
The levels of IL-17A in serum significantly increased at
6 h after LPS administration, reached the peak point at
12 h, and remained elevated at 24 h, as compared with
rats receiving saline (F4, 25 = 20.97, P < 0.001; saline group
7.04 ± 1.73 pg/ml, 6-h group 58.61 ± 7.37 pg/ml, 12-h
group 73.80 ± 5.70 pg/ml, 24-h group 55.35 ± 8.29 pg/ml,
P < 0.01, Fig. 2a). Similar effect was also observed in the
hippocampus for LPS-increased IL-17A expression that
occurred at 6, 12, and 24 h of stimulation, respectively,
when compared with the saline group (F4, 25 = 26.89,
P < 0.001; saline group 25.13 ± 5.62 pg/ml, 6-h group
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140.41 ± 10.59 pg/ml, 12-h group 161.66 ± 16.33 pg/ml,
24-h group 120.50 ± 11.55 pg/ml, P < 0.01, Fig. 2b).
These results indicate that IL-17A may be involved in
LPS-induced neuroinflammation.
IL-17A Abs improve LPS-induced memory impairment
To further evaluate the role of IL-17A on the LPS-induced
memory impairment model, rats were injected with IL-17A
Abs 30 min prior to LPS injection. One day after the LPS
injection, we performed contextual assessment and the Y-
maze test to observe the cognitive function of the rats. As
shown in Fig. 3a, b, the rats exposed to LPS exhibited a sig-
nificant reduction in cognitive function compared to ani-
mals exposed only to saline (freezing: F3, 20 = 14.92, P <
0.001; LPS group 30.00 ± 4.04 versus control group 60.17 ±
4.28, number of learning trials: F3, 20 = 15.19, P < 0.001;
LPS group 60.50 ± 5.69 versus control group 24.67 ± 4.36,
P < 0.01). In an attempt to ameliorate this LPS-induced
cognitive impairment, we injected IL-17A Abs 30 min
before LPS injection. Treatment with IL-17A Abs sig-
nificantly improved freezing behavior and the number
of learning trials, indicating it attenuated the memory
dysfunction caused by LPS (freezing anti-IL-17A + LPS
group 45.67 ± 2.80, number of learning trials anti-
IL-17A + LPS group 40.17 ± 3.36, P < 0.05, Fig. 3a, b).
Together, these results indicate that IL-17A is involved in
LPS-induced memory impairment and suggest a use for
IL-17A Abs in limiting the adverse cognitive outcomes
caused by endotoxemia.
Fig. 2 LPS-induced IL-17A expression in serum and in the hippocampus.
The rats were equally divided into five groups, the control group and
four LPS injection groups, according to four time points: 6, 12, 24, and
48 h after LPS injection. IL-17A protein levels in serum (a) and in the
hippocampus (b) were examined using ELISA. The data are presented as
the mean ± s.e.m. (n= 6 in a and b). **P< 0.01 versus saline group
Fig. 3 IL-17A Abs improved LPS-induced memory impairment.
a Contextual fear response, as measured by freezing behavior, was
determined in the rats. b The Y-maze test was performed after TFC
in the rats. The data are presented as the mean ± s.e.m. (n = 6 in
a and b). *P < 0.05, **P < 0.01 versus control group. #P < 0.05 versus
LPS treatment group
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IL-17A Abs inhibit the hippocampal TNF-α and IL-6
expression induced by LPS
To determine whether the IL-17A Abs could suppress
LPS-induced neuroinflammation in aged rats, protein levels
of TNF-α and IL-6 in the hippocampus were examined by
ELISA. As shown in Fig. 4a, b, following LPS injection for
1 day, levels of TNF-α and IL-6 in the hippocampus
significantly increased by up to approximately 731 and
329 % of the control values, respectively (TNF-α LPS
group 372.69 ± 16.64 pg/ml versus control group 50.99 ±
9.19 pg/ml, IL-6 LPS group 647.91 ± 30.38 pg/ml ver-
sus control group 196.66 ± 19.21 pg/ml, P < 0.01). Pre-
treatment with IL-17A Abs for 30 min partially abolished
the increase in LPS-induced TNF-α and IL-6 production
(TNF-α: F3, 20 = 97.89, P < 0.001; anti-IL-17A + LPS
group 226.04 ± 25.49 pg/ml, IL-6: F3, 20 = 78.14, P < 0.001;
anti-IL-17A + LPS group 437.99 ± 18.82 pg/ml, P < 0.01,
Fig. 4a, b). These results suggest that IL-17A Abs can
downregulate LPS-induced neuroinflammation.
IL-17A Abs reduce the LPS-induced increase in
Iba1-positive cells in hippocampal area CA1 and CA3
Coincident with the change in TNF-α and IL-6 expression
in the hippocampus, LPS injection also induced an increase
in Iba1-positive cells in area CA1 and CA3 of the hippo-
campus (CA1: F3, 12 = 44.36, P < 0.001; LPS group 25.5 ±
2.1 versus control group 4.5 ± 1.04, P < 0.01, CA3: F3, 12 =
28.39, P < 0.001; LPS group 20.25 ± 2.18 versus control
group 3.25 ± 0.95, P < 0.01, Fig. 5a, b). The microglia
exhibited enlarged cytoplasm and cell bodies, irregular
shapes, and intensified Iba1 staining, consistent with
the morphological characteristics of activated micro-
glia (Fig. 5a). This effect was significantly inhibited by the
IL-17A Abs (CA1: anti-IL-17A + LPS group 14.25 ± 1.75,
P < 0.01, CA3: anti-IL-17A + LPS group 10.25 ± 1.32, P <
0.01, Fig. 5a, b), suggesting that IL-17A Abs could suppress
the microglial activation induced by LPS injection.
IL-17A Abs inhibit COX-2, iNOS, BACE1, and APP expression
and increase the expression of PSD95 in the aged rats
treated with LPS
To investigate the inhibitory effect of the IL-17A Abs on
memory impairment via inhibition of neuroinflammation,
COX-2 and iNOS expression in the hippocampus were also
determined by Western blot analysis. Upon LPS treatment,
the expression of COX-2 and iNOS in the hippocampus of
LPS-injected rats was significantly higher than the expres-
sion in control rats, but these elevations were remarkably
inhibited by the IL-17A Abs (Fig. 6a, b). BACE1 and APP
play a key role in the process of amyloidogenesis. Therefore,
we examined the expression of BACE1 and APP in the
hippocampus. Western blot analysis showed that BACE1
and APP expression were significantly increased by LPS
injection in the rat brains, whereas densitometry data
showed that LPS-induced BACE1 and APP expression were
remarkably inhibited by the IL-17A Abs (Fig. 6a, b). The
expression of synaptic marker PSD95 was also evaluated in
the present study. We found that IL-17A Abs could in-
crease the expression of PSD95 in the aged rats treated with
LPS (Fig. 6a, b).
Effects of IL-17A on microglial activation and cytokine
production
Microglia play a pivotal role in neuroinflammation. To
investigate whether IL-17A could stimulate microglial
activation, microglia were cultured with various con-
centrations of IL-17A (1, 10, and 100 ng/ml) for 24 h.
Immunofluorescence analysis showed that IL-17A at a
concentration of 10 ng/ml or greater remarkably increased
Fig. 4 IL-17A Abs inhibited the hippocampal TNF-α and IL-6 expression
induced by LPS. TNF-α and IL-6 protein expression in serum (a) and in
the hippocampus (b) were determined by ELISA. The data are presented
as the mean ± s.e.m. (n= 6 in a and b). **P< 0.01 versus control group,
##P< 0.01 versus LPS treatment group
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Iba1 expression in microglia, suggesting that IL-17A can
induce microglial activation (MFI: F3, 12 = 79.06, P < 0.001;
medium group 10.01 ± 1.24, 1 ng/ml group 21.94 ± 1.61,
10 ng/ml group 29.07 ± 1.40, 100 ng/ml group 44.10 ±
2.04, Fig. 7a, b). Microglia-mediated neuroinflammation
occurs primarily due to excessive pro-inflammatory media-
tors and their downstream signaling cascades. Levels of
pro-inflammatory mediators were determined in the
present study. As shown in Fig. 7c, d, after incubation
with various concentrations of IL-17A for 24 h, the produc-
tion of TNF-α and IL-6 from primary microglial cells sig-
nificantly increased at an IL-17A concentration of 10 ng/ml
or greater (TNF-α: F3, 12 = 102.3, P < 0.001; medium group
24.89 ± 7.79 pg/ml, 10 ng/ml group 115.32 ± 7.55 pg/ml,
100 ng/ml group 210.30 ± 7.78 pg/ml, IL-6: F3, 12 = 149.8,
P < 0.001; medium group 58.39 ± 7.94 pg/ml, 10 ng/ml
group 168.44 ± 9.04 pg/ml, 100 ng/ml group 304.25 ±
12.85 pg/ml, P < 0.01), suggesting that IL-17A can upregu-
late the production of inflammatory factors.
Discussion
The role of IL-17A in neurodegenerative diseases such as
MS has been widely confirmed [22–24]; however, little is
known about whether IL-17A is involved in LPS-induced
neuroinflammation and cognitive impairment. In this
paper, we demonstrated that LPS could induce IL-17A ex-
pression in the CNS and that IL-17A Abs, which neutralize
IL-17A, suppressed neuroinflammation via the inhibition
of microglial activation in an LPS-induced in vivo model
and ameliorated memory impairment. In vitro, we found
Fig. 5 IL-17A Abs reduced the LPS-induced increase in Iba1-positive cells in hippocampal area CA1 and CA3. Hippocampal sections (10-μm) were
prepared 24 h after the LPS injection. a Representative immunohistochemistry graphs of microglia in area CA1 and CA3 of the hippocampus.
b Quantification of Iba1-positive cells in area CA1 and CA3 of the hippocampus. Graphs show the mean ± s.e.m. (n = 4). *P < 0.05, **P < 0.01 versus
control group, ##P < 0.01 versus LPS treatment group. Bar = 50 μm
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that IL-17A could stimulate microglial activation and the
production of pro-inflammatory cytokines.
It is well known that LPS can induce the production of
inflammatory cytokines, and LPS-induced systemic inflam-
mation in rats is frequently used as a model for studying
neuroinflammation and cognitive impairment. The release
of pro-inflammatory cytokines, such as TNF-α and IL-6,
has been implicated in LPS-induced systemic inflammation.
To data, intensive studies have been carried out regarding
the potential pro-inflammatory properties of IL-17A; for
example, IL-17A seems to be important in sepsis [25]. Flierl
et al. found that the levels of IL-17A in mice rose time
dependently in plasma after cecal ligation and puncture
(CLP), however, neutralization of IL-17A by the antibodies
improved sepsis (survival from ~10 to nearly 60 %), which
were associated with substantially significant reductions of
systemic pro-inflammatory cytokines and chemokines in
plasma. In the present study, we found that LPS could
increase the expression of IL-17A in serum. Interestingly,
the levels of IL-17A were also found increasing in the
hippocampus.
Recent studies have shown that IL-17A may play a role
in cognitive dysfunction [26–28]. IL-17A was associated
with poorer cognitive status in subjects with depressive
symptoms in ischemic stroke patients [26]. McManus et al.
found that respiratory infection could promote the infiltra-
tion of IL-17-producing T cells in older APP/PS1 mice,
which was accompanied by increased glial activation and
amyloid-β deposition [28]. Amyloid-β injection also could
increase the expression of IL-17A in the hippocampus,
accompanied with spatial memory impairment in rats [29].
Our results showed that the freezing behavior of animals
treated with LPS was decreased, whereas pretreatment with
IL-17A Abs was able to partially reverse the cognitive
Fig. 6 IL-17A Abs inhibit COX-2, iNOS, BACE1, and APP expression and increase the expression of PSD95 in the aged rats treated with LPS. a The
expression of COX-2, iNOS, BACE1, APP, and PSD95 was detected by Western blotting using specific antibodies in the hippocampus of rats. Each
blot is representative of three experiments. b Levels of COX-2, iNOS, BACE1, APP, and PSD95 were quantified and normalized to GAPDH levels.
Each value was then expressed relative to the control, which was set to 1. The data are presented as the mean ± s.e.m. **P < 0.01 versus control
group, ##P < 0.01 versus LPS treatment group
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deficits seen following LPS treatment. The freezing behav-
ior indicates that the rats recalled the learned fear when
placed in the same context [30]. Consistent with the TFC
results, the number of learning trials was increased in ani-
mals treated with LPS in Y maze; however, it was decreased
in animals pre-treated with IL-17A Abs compared to the
LPS-alone group. Therefore, the data presented here show
that IL-17A Abs administration could prevent the cognitive
deficits seen in LPS-treated animals. A previous report may
support our observation above. In a surgery model, Tian et
al. found that partial hepatectomy also could increase the
levels of IL-17A in the hippocampus and induce cognitive
impairment in mice, while vitamin D ameliorated cognitive
dysfunction through inhibiting Th17 cells accompanied
with expansion in Treg cells [27]. These in vivo experi-
ments indicate that IL-17A may be involved in LPS-
induced cognitive impairment and may play a detrimental
role in it.
Cognitive decline is prominent in Alzheimer’s dis-
ease (AD) and also occurs in other disorders in which
Fig. 7 Effects of IL-17A on microglial activation and cytokine production. Primary microglial cells were incubated with IL-17A at 1, 10, and
100 ng/ml for 24 h. a The cells were stained with an Iba1 antibody. Upregulated Iba1 expression (green) in activated microglia was observed using
confocal scanning. The blue staining represents DAPI. Scale bar = 50 μm. b Graph showing the mean fluorescence intensity (MFI) for Iba1. c, d
Quantification of TNF-α and IL-6 in the media. The data are presented as the mean ± s.e.m. of four independent experiments. **P < 0.01 versus
the response to medium alone
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neuroinflammation is believed to play a prominent role
[31]. Thus, the next step was to evaluate the effects of the
IL-17A Abs on the neuroinflammatory processes induced
by LPS administration. Recently, several researchers were
reported that systemic administration of LPS induces
release of pro-inflammatory mediators and cytokines
such as TNF-α, IL-6, iNOS, and COX-2 in the brain,
indicating that systemic inflammation induces neuroinflam-
mation [32]. Moreover, systemic administration of LPS has
been reported to result in increased APP processing as well
as memory deficiency with concomitant increased neuroin-
flammation [33]. Administration of non-steroidal anti-
inflammatory drugs (NSAIDs) could reduce the risk and
delay the onset of AD [34, 35]. Thus, anti-inflammation
could decrease memory deficiency via the prevention of
neuroinflammation. In the present study, we found that
pre-treatment with IL-17A Abs significantly inhibited the
LPS-induced expression of TNF-α, IL-6, iNOS, and COX-
2 in the hippocampus. APP is the source of extracellular
amyloid-β plaques, which are believed to cause damage to
neurons, especially to neuronal synapses [36]. BACE1 is
the rate-limiting enzyme for the formation of amyloid-β
[37]. Expression of APP and BACE1 has been shown to be
increased in neuroinflammation and to be involved in
cognitive impairment [38]. We found that pre-treatment
with IL-17A Abs significantly inhibited the LPS-induced
expression of APP and BACE1, increased LPS-induced
decline of PSD-95, alleviated neuronal synapses damage.
IL-17A is believed to have a particular role in the de-
layed phase of the post-infarct inflammatory cascade. A
significantly higher number of IL-17A-expressing cells
in ischemic tissue has been detected in postmortem
studies in both humans and rodents [39, 40]. Shichita
et al. demonstrated that IL-17A-deficient mice showed
a reduction in infarct volumes and levels of TNF-α and
IL-1β in the brain [41]. Zong et al. found that IL-17A
could promote spinal cord neuroinflammation after spinal
cord injury [42]. Overexpression of IL-17A in astrocytes
could lead to increase in LPS-induced neuroinflammation
in vivo [43]. While blocking Th-17 cells trafficking attenu-
ates neuroinflammation after LPS/hypoxic-ischemic [44].
Taken together, these in vivo experiments point to a detri-
mental role of IL-17A in LPS-induced neuroinflammation
and inhibition of IL-17A expression could partially prevent
neuroinflammation.
Microglia, important immune cells in the CNS, are
regarded as the tissue macrophages of the brain. Within
the aged brain, microglia are primed and easily produce
a more violent response to inflammatory stimulation
[45]. Microgliosis, which is defined as an increased number
of microglia, is an important response of neuroinflamma-
tion [46]. In our in vivo study, the number of Iba1-positive
cells in hippocampal area CA1 and CA3 increased in aged
rats subjected to LPS, which is consistent with the
overproduction of pro-inflammatory cytokines and pro-
teins in the hippocampus and with the sharp decline in be-
havioral performance. IL-17A Abs pre-treatment
reversed the hippocampal microgliosis induced by
LPS. These results indicate that IL-17A may be in-
volved in LPS-induced microglial activation. To investi-
gate whether IL-17A can induce microglial activation or
not, we used recombinant IL-17A protein to stimulate
microglia for 24 h in vitro. We found that IL-17A could in-
duce microglial activation and increase the expression of
pro-inflammatory cytokines in microglia in a dose-
dependent manner. A previous report that LPS signifi-
cantly induced IL-17A expression in BV-2 microglial cell
line may support our observation above [47]. The study by
Kawanokuchi et al. demonstrated that microglia express
the IL-17A receptor. They also showed that IL-17A could
upregulate the expression of IL-6 mRNA in microglia in
vitro [48]. Murphy et al. also found that myelin oligo-
dendrocyte glycoprotein (MOG)-induced IL-17A-
producing Th1/Th17 cells could stimulate microglial acti-
vation and pro-inflammatory cytokine production; how-
ever, MOG-induced IFN-γ-producing Th1 cells could not
stimulate the activation of microglia in vitro [49]. Zimmer-
mann et al. have also shown that overexpression of IL-
17A in astrocytes led to microglial activation either follow-
ing LPS challenge or not in vivo [43]. These findings indi-
cate that IL-17A could induce microglial activation, which
have been confirmed to play a key role in neurodegen-
erative diseases and cognitive impairment [45]. How-
ever, another study by Prajeeth et al. showed that
effector molecules released by Th1 but not Th17 cells
drive an M1 response in microglia in vitro [50]. This
study could not demonstrate that IL-17A has no effect
on microglial activation, because both Th1 and Th17
cells could produce various cytokines, which achieved
a complex effect on microglia.
Conclusions
In conclusion, our results suggest that IL-17A is involved in
LPS-induced neuroinflammation and cognitive impairment
in aged rats via microglial activation. Anti-IL-17A may be a
new therapeutic strategy for the treatment of endotoxemia-
induced neuroinflammation and cognitive dysfunction.
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